ASE Technology Holding Co., Ltd. — FY2022 Form 20-F
Reporting period: Fiscal year ended December 31, 2022. Although the request references 2022 Q4, this filing is an annual report; quarterly figures below are unaudited. Financial statements are prepared under IFRS as issued by the IASB and reported in New Taiwan dollars (NT$).
Business context and reporting period
ASE provides semiconductor packaging and testing, interconnect materials, and electronics manufacturing services (EMS). FY2022 revenue growth reflected increased demand for advanced packaging, wafer probing, and EMS orders. Taiwan generated 58.5% of operating revenue by production location; the U.S. accounted for 66.5% of revenue based on customer headquarters.
Key financial metrics
| Metric | FY2022 | FY2021 | Change |
|---|---|---|---|
| Operating revenue | NT$670.9bn | NT$570.0bn | +17.7% |
| Gross profit / margin | NT$134.9bn / 20.1% | NT$110.4bn / 19.4% | Profit +22.3% |
| Operating profit / margin | NT$81.2bn / 12.1% | NT$63.3bn / 11.1% | Profit +28.2% |
| Profit for year | NT$64.6bn | NT$62.2bn | +3.8% |
| Profit attributable to owners | NT$61.5bn | NT$60.2bn | +2.2% |
| Diluted EPS / equivalent ADS | NT$13.81 / NT$27.61 | NT$13.54 / NT$27.07 | Higher |
| Operating cash flow | NT$111.0bn | NT$81.7bn | Higher |
| Capital expenditures (cash paid) | NT$72.6bn | NT$70.9bn | Higher |
Q4 context: FY2022 Q4 revenue was NT$177.4bn and gross profit NT$34.1bn, for a 19.2% gross margin. Q3 revenue was NT$188.6bn and gross profit NT$38.0bn, with a 20.1% margin; Q4 2021 revenue was NT$172.9bn and gross profit NT$32.9bn, with a 19.0% margin.
Revenue mix: Packaging contributed 45.3% of FY2022 revenue, testing 8.3%, and EMS 45.0%. Packaging revenue rose 11.5%, testing 12.0%, and EMS 26.1%. Segment gross margins were 27.1% for packaging, 37.6% for testing, and 9.6% for EMS.
Liquidity and debt at year-end: Cash and cash equivalents were NT$58.0bn; current financial assets were NT$6.8bn; working capital was NT$71.0bn; unused credit lines were NT$346.0bn. Reported total debt was NT$202.3bn, including NT$46.7bn short-term debt, NT$11.0bn current long-term debt, and NT$144.5bn long-term debt. Assets of NT$23.4bn were pledged as collateral. The company reported no financial covenant breach.
Material changes versus the prior comparable period
- Gross and operating margins improved, which management attributed mainly to NT-dollar depreciation, higher loading, and operating efficiency. Raw materials rose to 52.1% of revenue from 49.3%, partly reflecting EMS product mix.
- Owners’ profit grew only 2.2%, despite stronger operating profit. Net non-operating income fell to NT$0.6bn from NT$16.9bn, largely because FY2021 included a NT$17.3bn gain on China-site disposals; FY2022 also had higher finance costs and foreign-exchange losses.
- ASE recorded net foreign-exchange losses of NT$2.46bn in 2022, versus gains of NT$1.40bn in 2021.
- Operating cash flow increased, while investing cash outflow rose to NT$74.0bn, principally because of capital spending and the absence of prior-year disposal proceeds. Financing cash outflow was NT$62.5bn, including NT$30.0bn of dividends paid.
- Inventory increased to NT$87.3bn from NT$67.8bn. Management identified inventory changes as a significant offset to operating cash generation.
Outlook, management commentary, risks, and unusual items
- The filing provides no specific revenue or earnings guidance. Management stated that cash, expected operating cash flow, short-term investments, and credit facilities should cover existing operations, commitments, and cash requirements for at least the next 12 months. 2023 capital spending is expected to be financed from these sources and credit lines; the filing does not provide a specific total 2023 capex forecast.
- Management intends to continue capacity expansion and R&D investment in advanced packaging, testing, and EMS. FY2022 R&D expense was NT$24.4bn, or 3.7% of revenue. Capital-expenditure commitments were NT$59.7bn at year-end, excluding approximately NT$28.1bn of construction commitments whose payment schedule was not readily estimable.
- Principal risks include semiconductor-industry cyclicality, pricing and capacity utilization, customer concentration (the five largest customers represented 50.2% of revenue), raw-material and substrate availability, technology competition, foreign exchange, Taiwan–China tensions, and Taiwan earthquake, drought, and power-supply exposure. The filing states that the company had not been materially affected by global trade tensions, military conflicts, or pandemics as of the report date.
- Environmental matters include prior wastewater proceedings. The 2020 reimposed NT$47.0m fine was revoked in December 2020 and remanded for further administrative action; the filing does not report a final replacement outcome. A separate China environmental-pollution case concluded in 2021, with the subsidiary’s fine and benefit repayment recognized.
- Legal proceedings involving director and COO Tien Wu remained pending on appeal/remand: a criminal insider-trading matter, a director-removal case, and a civil class action. The filing describes an August 2022 partial damages ruling in the class action, appealed by defendants.
- Cash consideration receivable from the 2021 China-site disposal had a scheduled due date of March 17, 2023. A March 2023 supplemental agreement provided for an affiliate to offer shares instead; if it fails to do so within 12 months, payment is due within five further months.
- The board approved a proposed FY2022 cash dividend of NT$8.8 per share on March 30, 2023, subject to adjustment for changes in shares outstanding. The FY2022 dividend paid was NT$7.0 per share.
- The independent auditor issued an unqualified opinion on the IFRS financial statements and an unqualified opinion on internal control over financial reporting. Goodwill of NT$52.3bn was a critical audit matter; no impairment was recognized for the packaging and testing segments.
Important facts for investors to verify
- Review the full audited statements and notes for debt maturities, variable-rate exposure, liquidity, and the assumptions supporting the company’s capacity to fund capital spending and commitments.
- Track inventory levels, EMS margins, raw-material costs, utilization, and customer concentration for evidence of demand or working-capital deterioration.
- Confirm collection or alternative settlement of the China-site disposal receivable and assess any related indemnity or execution risks.
- Check subsequent court and regulatory developments in the Tien Wu proceedings and environmental matters, including any financial or governance consequences.
- Assess goodwill valuation sensitivities and whether future demand, discount rates, or capacity utilization could trigger impairment.
- Confirm approval, final per-share amount, and payment timing of the proposed NT$8.8 dividend.